Brief: Medicenna Presents Additional Phase 2B Clinical Data At Glioblastoma Drug Development Summit
12/12/2019 13:56
Dec 12 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA PRESENTS ADDITIONAL ENCOURAGING PHASE 2B
CLINICAL DATA
AT INAUGURAL GLIOBLASTOMA DRUG DEVELOPMENT ANNUAL SUMMIT
* MEDICENNA - MDNA55 ACHIEVES UP TO 5 FOLD INCREASE IN 12
MONTH
SURVIVAL RATE IN CHEMOTHERAPY RESISTANT GLIOBLASTOMA COMPARED TO
APPROVED THERAPIES
Source text for Eikon: ID:nPn9tvfX1a
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results